Neurobehavioral Disorders
An additional 53.2 million cases of major depressive disorder and 76.2 million cases of anxiety disorders globally were estimated due to the COVID-19 pandemic.
Sleep Disorders
Differences in sleep patterns, which can be objectively measured with wrist-worn accelerometers, are the norm among patients with lifetime psychiatric conditions.
Neurobehavioral Disorders
Researchers compared the effects of 4 contemporary ablative neurosurgical procedures on treatment-resistant psychiatric symptoms.
Neurobehavioral Disorders
Use of ketamine and esketamine for their antidepressant effects does not seem to have harmful neurocognitive effects in individuals with treatment-resistant depression.
Neurobehavioral Disorders
The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain.
Neuropathy
This systematic review and meta-analysis of randomized controlled trials assessed the efficacy and safety of gabapentin and duloxetine for treating patients with painful diabetic peripheral neuropathy.
Epilepsy
Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.
Neurobehavioral Disorders
The FDA has cleared Nexstim's NBT system for the treatment of major depressive disorder.
Neurocognitive Disorders
Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.
ECTRIMS 2015
Changes to brain structure indicate possible underlying connection to idiopathic major depressive disorder.
